Edge Wealth Management’s Lexaria Bioscience LEXX Stock Holding History

Edge Wealth Management’s Portfolio LEXX Stock Details LEXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,333	Closed	-$13K	–	286
2021 Q4	$13K	Hold	3,333	–	–	﹤0.01%	283
2021 Q3	$21K	Hold	3,333	–	–	﹤0.01%	261
2021 Q2	$24K	Hold	3,333	–	–	﹤0.01%	256
2021 Q1	$19K	Buy	+3,333	New	+$19.5K	﹤0.01%	273

Other funds holding LEXX

ICM

Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

APC

Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return

Edge Wealth Management's LEXX Position: Q1 2022 in Review

Edge Wealth Management sold out of Lexaria Bioscience (LEXX) in Q1 2022, closing a stake of 3,333 shares — an estimated $13K sold.

Edge Wealth Management first reported a position in LEXX in Q1 2021 and held it in 4 quarters. The position peaked at $24K in Q2 2021. 12 funds tracked by Wall St. Rank hold LEXX as of Q1 2022.

Edge Wealth Management reported no remaining Lexaria Bioscience position as of Q1 2022 after selling out during the quarter.
Edge Wealth Management sold 3,333 Lexaria Bioscience shares in Q1 2022, an estimated $13K.
Edge Wealth Management first reported a position in Lexaria Bioscience in Q1 2021 and held it in 4 quarters.
Edge Wealth Management's Lexaria Bioscience position peaked at $24K in Q2 2021.
12 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q1 2022.

Based on Edge Wealth Management's 13F filing for Q1 2022, filed 14 Apr 2022.